Prudential Financial, Inc. to Announce Second Quarter 2025 Earnings; Schedules Conference Call
Members of Prudential's senior management will host a conference call on Thursday, July 31, 2025, at 11:00 a.m. ET to discuss with the investment community the company's second quarter results.
Conference Call Information
The conference call will be broadcast live over the company's Investor Relations website at investor.prudential.com. Please log on 15 minutes early in the event necessary software needs to be downloaded.
Institutional investors, analysts, and other interested parties are invited to listen to the call by dialing one of the following numbers:
Domestic: (877) 407-8293 (Toll Free)
International: (201) 689-8349
Replay Information
The call will be made available from 3:00 p.m. ET on July 31 through August 14 via the following numbers:
Domestic: (877) 660-6853 (Toll Free)
International: (201) 612-7415
Replay Code: 13754272
A replay will also be available on the Investor Relations website through August 14. Questions may be directed to Investor Relations at investor.relations@prudential.com.
Prudential Financial, Inc. (NYSE: PRU), a global financial services leader and premier active global investment manager with approximately $1.5 trillion in assets under management as of March 31, 2025, has operations in the United States, Asia, Europe, and Latin America. Prudential's diverse and talented employees help make lives better and create financial opportunity for more people by expanding access to investing, insurance, and retirement security. Prudential's iconic Rock symbol has stood for strength, stability, expertise, and innovation for 150 years. For more information, please visit news.prudential.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
26 minutes ago
- Business Insider
UBS Sticks to Its Buy Rating for Targa Resources (TRGP)
In a report released on July 10, Manav Gupta from UBS reiterated a Buy rating on Targa Resources, with a price target of $228.00. The company's shares closed last Friday at $171.90. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Gupta covers the Energy sector, focusing on stocks such as DT Midstream, Cheniere Energy, and Imperial Oil. According to TipRanks, Gupta has an average return of 1.4% and a 60.43% success rate on recommended stocks. In addition to UBS, Targa Resources also received a Buy from Barclays's Theresa Chen in a report issued on July 10. However, on July 7, TD Cowen initiated coverage with a Hold rating on Targa Resources (NYSE: TRGP). TRGP market cap is currently $37.29B and has a P/E ratio of 31.59. Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TRGP in relation to earlier this year. Most recently, in May 2025, D. Scott Pryor, the President – Logistics and Transportation of TRGP sold 20,000.00 shares for a total of $3,232,750.00.
Yahoo
an hour ago
- Yahoo
Johnson & Johnson (JNJ): I Would 'Love' If Trump Praised The Company, Says Jim Cramer
We recently published . Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the largest and most well-known pharmaceutical companies in the world. Its shares have gained a modest 8.9% year-to-date as the firm has struggled from headwinds such as a judge rejecting its $10 billion talc powder cancer lawsuit settlement. In his previous comments about Johnson & Johnson (NYSE:JNJ), Cramer has called the firm one of the 'best-run companies in America' and praised its balance sheet and drug pipeline. This time around, he discussed the upcoming earnings report and an analyst note: '[On a Mizuho note saying POTUS would praise LLY and JNJ] I would love that, that won't happen. You know why it won't happen? See there's someone in the health and human services department that's not crazy about, about big pharma and the way we think about it. 'JNJ, JNJ I don't know. JNJ's going to report this week they've got a talc problem still but I thought the President was going to act against the plaintiffs, probably has.' A smiling baby with an array of baby care products in the foreground. As for Johnson & Johnson (NYSE:JNJ) 's balance sheet and pipeline, here's what Cramer said: 'Or let's consider Johnson & Johnson, triple A balance sheet, many drugs in the pipeline, one of the best-run companies in America, if not the world, with perhaps the most billion-dollar franchises of any pharmaceutical company I know, but JNJ only yields 3.55%, and it's got this terrible legal overhang related to allegations that its talcum powder, no longer in the market, caused ovarian cancer. We don't know how open-ended the claims are. Can you tolerate that risk? I'd love to say just go buy JNJ, but where? What price? That yield is no longer enough to compensate you for the risk, especially if you don't know if RFK Jr dislikes some of their drug delivery mechanisms and formulas, so people are staying away from that, too, not just because of the bonds. JNJ… 3.3%.' While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
3 hours ago
- Business Insider
Thermo Fisher (TMO) Gets a Buy from Wells Fargo
In a report released on July 11, Brandon Couillard from Wells Fargo maintained a Buy rating on Thermo Fisher, with a price target of $570.00. The company's shares closed last Friday at $434.86. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Couillard covers the Healthcare sector, focusing on stocks such as Exact Sciences, Thermo Fisher, and Maravai Lifesciences Holdings. According to TipRanks, Couillard has an average return of 14.9% and a 60.65% success rate on recommended stocks. In addition to Wells Fargo, Thermo Fisher also received a Buy from Evercore ISI's Vijay Kumar in a report issued on July 8. However, on July 11, Scotiabank downgraded Thermo Fisher (NYSE: TMO) to a Hold. The company has a one-year high of $627.88 and a one-year low of $385.46. Currently, Thermo Fisher has an average volume of 2.74M.
